These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27478536)

  • 1. New horizon for radical cure of chronic hepatitis B virus infection.
    Tajiri K; Shimizu Y
    World J Hepatol; 2016 Jul; 8(21):863-73. PubMed ID: 27478536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.
    Yang HC; Kao JH
    Emerg Microbes Infect; 2014 Sep; 3(9):e64. PubMed ID: 26038757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus.
    Wang G; Guan J; Khan NU; Li G; Shao J; Zhou Q; Xu L; Huang C; Deng J; Zhu H; Chen Z
    Gut Pathog; 2021 Apr; 13(1):22. PubMed ID: 33845868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
    Xia Y; Stadler D; Lucifora J; Reisinger F; Webb D; Hösel M; Michler T; Wisskirchen K; Cheng X; Zhang K; Chou WM; Wettengel JM; Malo A; Bohne F; Hoffmann D; Eyer F; Thimme R; Falk CS; Thasler WE; Heikenwalder M; Protzer U
    Gastroenterology; 2016 Jan; 150(1):194-205. PubMed ID: 26416327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aiming for cure in HBV and HDV infection.
    Petersen J; Thompson AJ; Levrero M
    J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure.
    Shinn BJ; Martin A; Coben RM; Conn MI; Prieto J; Kroop H; DiMarino AJ; Hann HW
    World J Hepatol; 2019 Jan; 11(1):65-73. PubMed ID: 30705719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection.
    Morikawa K; Shimazaki T; Takeda R; Izumi T; Umumura M; Sakamoto N
    Ann Transl Med; 2016 Sep; 4(18):337. PubMed ID: 27761441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting Hepatitis B Virus: Challenges of Curative Therapies.
    Hu J; Protzer U; Siddiqui A
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus infection: An insight into infection outcomes and recent treatment options.
    Noordeen F
    Virusdisease; 2015 Jun; 26(1-2):1-8. PubMed ID: 26436115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies for chronic hepatitis B.
    Bitton Alaluf M; Shlomai A
    Liver Int; 2016 Jun; 36(6):775-82. PubMed ID: 26854115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?
    Korkmaz P; Asan A; Karakeçili F; Tekin S; Demirtürk N
    Infect Dis Clin Microbiol; 2023 Dec; 5(4):267-280. PubMed ID: 38633851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the Interactions of HBV cccDNA with Host Factors.
    Mohd-Ismail NK; Lim Z; Gunaratne J; Tan YJ
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.